Lodine has been approved for the treatment of rheumatoid arthritis. Lodine is a nonsteroidal anti-inflammatory drug (NSAID).
At the same time the FDA has cleared for market a new 500 mg dosage strength.
The safety and efficacy of Lodine in relieving the signs and symptoms of rheumatoid arthritis were established in a three-year, double-blind, multicenter clinical trial involving 1,446 subjects with active rheumatoid arthritis. Data from the study indicated that doses of Lodine at 1,000 mg/day were efficacious and well tolerated in subjects being treated for active rheumatoid arthritis.
The Lodine (etodolac) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.